Aratana Therapeutics Inc (PETX)

7.62
NASDAQ : Health Care
Prev Close 7.54
Day Low/High 7.50 / 7.76
52 Wk Low/High 2.56 / 10.73
Avg Volume 438.40K
Exchange NASDAQ
Shares Outstanding 37.04M
Market Cap 279.31M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

7 Low-Priced Stocks to Watch in 2017

7 Low-Priced Stocks to Watch in 2017

Good picks make it easier to produce good results, but they are just a starting point.

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

Aratana Therapeutics Enters Oversold Territory (PETX)

Aratana Therapeutics Enters Oversold Territory (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of PETX January 2017 Options Trading

First Week of PETX January 2017 Options Trading

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new January 2017 contracts and identified the following put contract of particular interest.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

Shark Bites: As Market Calms Down, Time to Shift Gears

Shark Bites: As Market Calms Down, Time to Shift Gears

Emotions are becoming less of an issue.

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.

Trader Be Nimble, Trader Be Quick

Trader Be Nimble, Trader Be Quick

The trading action remains quite tedious, though there are short-term opportunities out there.

In a Breakdown Like This, Focus on Preventing Further Losses

In a Breakdown Like This, Focus on Preventing Further Losses

If you control your risk, then the returns will come.

Shark Bites: Versartis Is a Biotech Worth Tracking

Shark Bites: Versartis Is a Biotech Worth Tracking

Biotechnology stocks can be risky but it's helpful to track them over time.

Disinterest and Lethargy Are Guiding This Market

Disinterest and Lethargy Are Guiding This Market

Breadth is running very poor -- at more than 2 to 1 negative.

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Shark Bites: Big Market Move May Be in the Making -- Clear the Decks!

Slew of news hasn't created much action.

Shark Bites: Not Much Reason to Buy in This Environment

I'm even staying away from the appealing stocks.

For Traders, Planning Is More Important Than the Plan

For Traders, Planning Is More Important Than the Plan

Because every stock has a unique personality that requires its own strategy.

Shark Bites: Stock Picking Makes a Comeback

Market ends the week with some profit-taking.

Interesting PETX Put And Call Options For May 2017

Interesting PETX Put And Call Options For May 2017

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the May 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.